Capital World Investors Sells 369,004 Shares of KalVista Pharmaceuticals, Inc. $KALV

Capital World Investors reduced its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 11.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 2,808,583 shares of the specialty pharmaceutical company’s stock after selling 369,004 shares during the period. Capital World Investors owned approximately 0.06% of KalVista Pharmaceuticals worth $45,359,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in KALV. AQR Capital Management LLC bought a new position in shares of KalVista Pharmaceuticals in the first quarter worth $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of KalVista Pharmaceuticals by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock worth $281,000 after acquiring an additional 2,939 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock worth $3,923,000 after acquiring an additional 12,263 shares during the period. Creative Planning boosted its holdings in shares of KalVista Pharmaceuticals by 20.0% in the second quarter. Creative Planning now owns 33,380 shares of the specialty pharmaceutical company’s stock worth $377,000 after acquiring an additional 5,573 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of KalVista Pharmaceuticals by 2.8% in the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after acquiring an additional 1,458 shares during the period.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CFO Brian Piekos sold 1,489 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $26.78, for a total transaction of $39,875.42. Following the sale, the chief financial officer owned 21,661 shares in the company, valued at $580,081.58. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Nicole Sweeny sold 1,489 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $26.78, for a total value of $39,875.42. Following the sale, the insider owned 59,291 shares in the company, valued at $1,587,812.98. The trade was a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 254,602 shares of company stock worth $4,656,670. Company insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $26.99 on Wednesday. The business’s 50-day moving average price is $23.71 and its two-hundred day moving average price is $18.54. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.83 and a twelve month high of $27.00. The stock has a market cap of $1.44 billion, a P/E ratio of -7.80 and a beta of -0.12. The company has a quick ratio of 5.10, a current ratio of 5.17 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $40.86 million during the quarter, compared to analysts’ expectations of $39.03 million. As a group, equities analysts predict that KalVista Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Needham & Company LLC lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 30th. Leerink Partners cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. JonesTrading cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. HC Wainwright cut KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $37.00 to $27.00 in a report on Friday, May 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, KalVista Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $30.60.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.